跳至主要内容
临床试验/CTRI/2019/01/017326
CTRI/2019/01/017326尚未招募未知

Short course steroid as add-on drug in treatment of chronic migraine- randomised placebo controlled study.

ational Institute of Mental Health and NeuroSciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Chronic migraine patients meeting the criteria according to ICHD-3 (2013) on prophylaxis for a period of at least 3months.

排除标准

  • -Medical conditions that increase the risk of steroid administration like-Diabetes Mellitus (operationally defined as FBS >140; PPBS >200mg/dl), Impaired glucose tolerance (postprandial glucose levels of 140 to 199 mg per dL), Impaired fasting glucose (glucose levels of 100 to 125 mg per dL in fasting patients), Active infections, Hypertension( >140/90mmHg),Chronic co-morbidities that might be affected by steroids or would make changes in the clinical or biochemical values that would likely unmask the blinding. Diagnosis of secondary headache, Complicated migraine, Beck Depression Inventory (BDI) >24 (moderate depression)

研究者

发起方
ational Institute of Mental Health and NeuroSciences

相似试验